UK Markets open in 3 hrs 31 mins

QIAGEN N.V. (QGEN)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
54.34+0.19 (+0.35%)
At close: 4:00PM EDT
Sign in to post a message.
  • M
    Michael
    $TCRR conversation
    $TCRX has a Negative $40 million enterprise value. SLIDE 42 of attached TCRX presentation states TCRX has $197 million of cash and 23.9million shares and No debt.

    TCRX ALSO HAS A Tcell technology platform with partnerships with $NVS and $QGEN.

    TCRX is a better company than TCRR, in my view.

    https://ir.tscan.com/static-files/821fcfd9-7ee3-4924-8366-a0280d467f6d
  • M
    Michael
    $TCRX conversation
    According to Slide 42 of TCRX’s September investor presentation (Weblink below), TCRX has $196.7 million in cash and no debt. TCRX has 23.9 million shares outstanding. This equates to $8.20 in cash per share. The share price is only $8.21.

    Tcrx also hinted at a few new partnerships in the coming months and possibly news on a new COVID vaccine with a new partner and a diagnostic test with $QGEN

    Seems like there is a lot of good things in this company that is trading at its cash. Aloe per share.

    https://ir.tscan.com/static-files/821fcfd9-7ee3-4924-8366-a0280d467f6d
  • M
    Mystery
    So it got EUA today. Why isn't the stock going up?
    I bought few shares and it's actually going down slightly.
    What say you?
  • A
    Always Right
    $BNGO conversation
    Great overview on sequencing versus mapping from here:
    https://www.reddit.com/r/BNGO/comments/l49l79/found_this_guy_on_twitter_he_explains_bngo_so/

    "
    First, the Saphyr mapper is not a sequencer, it is, as its name say, a mapper. The difference of a genome sequence and a genome map is that the map aids to decipher the sequence more accurately (for sequence I refer to billions of ATCGATCG…).

    A genome map is created before the sequencing begins and provides confidence in the sequence obtained. Therefore, the Saphyr mapper, does not compete or substitute any sequencing technology (either from $PACB, $ILMN, $TMO, etc.), but rather it is —COMPLEMENTARY— to it.

    For an analogy, think of an any given address. Imagine I live at 14th Main street, Springfield, Massachusetts, USA. And someone asks me where I live, and I simply answer “Springfield”. If the person is local of Massachusetts, will probably assume that I live in Springfield MA.

    However, if I’m asked in a state other than MA, and the person is from a state other than MA, will probably ask “which Springfield”, as there are many cities with this name in all USA; I would have to specify “Springfield, MA.”

    If you are familiar with the locality, you will probably assume its broader location. I use this analogy because almost every city in USA has a “Main” street; a lot of states have a “Springfield” city; but also, Main street in Springfield do exists in countries other than USA.

    Following this analogy, if we asked, “what is your address?” the most common different sequencing technologies will give, with great precision, the following answers: $ILMN — 14th Main. $TMO — 14th Main. $QGEN — 14th Main. $PACB — 14th Main, Springfield.

    None of the above will mention “MA, USA”. Is it possible to locate the accurate address with the first three? NO. Is it possible to locate it with PACB? NOT ENTIRELY.

    In the same analogy, if you asked the Saphyr mapper “what is your address?” the answer will be:

    $BNGO — Near Main, Springfield, MA, USA.

    Would you be able to know the precise address? NO. Therefore, there is no technology that could give a complete and accurate answer, yet.

    10) Then why is Bionano’s such a big deal? Because currently, the most common tools for mapping at hospitals and clinics around the world are FISH (fluorescent in situ hybridization), DNA microarrays (commonly known as CMA), chromosome banding (CB), and Karyotypes;

    11) these techniques have existed for at least 20 years and have been the state of the art, so far. What they all have in common is that they are laborious, time consuming and will answer the following to the question “what is your address?”:

    12)

    Karyotype — USA

    Microarays — Springfield

    FISH — MA

    Cromosome banding — Springfield or MA.

    Why is it that people compare Saphyr to PACB? As you can see, the state of the art for the highest precision was held by PACB, but still it won’t give a fully accurate address.

    13) So, if hospitals and clinics around the world needed to figure out what is wrong with your genes at a large scale with the most accurate map/sequence, the only option was PACB.

    14) The biggest disadvantage, however, is that, from all technologies mentioned, PACB is the most expensive and time consuming, and it needs a special expertise that is difficult to find in sequence analysis, hence not many clinics or hospitals even offer this service.

    15) Why is Bionano’s tech the such a big deal? Because it is only as expensive as any of the other mapping tools, it is high throughput, it covers the entire genome(s) at once, it is automated, and it is way more precise than FISH, CMA, CB, and Karyotypes ALL TOGETHER.

    16) Finally, the Saphyr mapper will inexorably find chromosomal re-arrengements missed by PACB—as we all have seen it in their webinars and scientific papers— because they resemble that Springfield was erroneously located in MA, USA—but is rather located in Chelmford, UK.

    17) Why is such a game changer then? Because, if combined, a Saphyr mapper and a sequencing technology (see above) will never miss a mutation or chromosome rearrangement — for large or small this is.

    18) My forecast for the upcoming years is that there will be a massive adoption of mapping tech at hospitals and clinics around the world in the next 5-10 years, which will substitute entirely FISH, CMA, CB, and Karyotypes.

    19) Maybe, if Bionano’s tech is the only one offering optical imaging, it will dominate the entire industry for years.

    As for $BNGO stock price, I have no idea; I am only a scientist that happens to trade.The stock market behaves in ways unpredictable to me.

    20) The only thing I'm certain is that Bionano’s tech is highly disruptive in its niche. And, if there is one thing I've learned from the Market, is that one thing is the company, another thing is its product/service, and a way different beast is its stock price.

    "
  • J
    Jon
    Sold Codx because too many red flags. 20 employees, low quality site and promo videos. The co founders sounded high, one of the describing scientific process with words like "stuff" and "this thing" really? found it weird that with 25mil shares outstanding volume is well over 70mil each day past 6 days. then they issue more stock at market. Bought the real deal in Qgen. hope to see some hood exposure. Good luck to us.
  • f
    fpr58
    Qaigen products mention in CDC Docs for coronavirus testing panel along with this disclaimer. I find it hard to believe that Qiagen is mentioned merely as an example when there is such a limited market of coronavirus testing kits.

    "Disclaimer: Names of vendors or manufacturers are provided as examples of suitable product sources. Inclusion does not imply endorsement by the Centers for Disease Control and Prevention."

    Real-Time RT-PCR Panel for Detection 2019-Novel Coronavirus
    https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html

    Even more Qaigen products are listed in this doc that has more procedures

    CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel
    Instructions for Use Catalog # 2019-nCoVEUA-01 1000 reactions For In-vitro Diagnostic (IVD) Use Rx Only
    https://www.fda.gov/media/134922/download
  • A
    Anonymous
    $SGMD upward movement expected after financials on the 22nd
    Sugarmade has a 40% stake with an option to increase the ownership to 70% in Budcars which has a near 5/5 rating on multiple websites and growing quarter over quarter very rapidly. Also, an expansion of Budcars services to new territories will be announced any time soon. We’re talking millions and millions in revenue. Lastly, they will also grow and sell their own cannabis products which they will announce sometime this year.
    FUTURE LOOKS BRIGHT
  • l
    luma
    $CODX may be next as soon as Americans start listening to medical scientists rather than Wall St analysts regarding worldwide demand for accurate Covid 19 tests. CODX only has 12M shares outstanding. Looking for parabolic?
  • c
    cass
    can anyone explain why this company stock prices isn't moving like other testing and mask makers go parabolic?
  • D
    DavidT
    Ellume just got a $230 million dollar contract to ramp up production - LIVE CDC Press Conference!
  • j
    jamie
    On Bloomberg suitors may still be interested. Qgen no doubt holding out for higher bid.
  • J
    Just
    Just saw Qgen on CNBC, they’ve been asked to distribute their test kits for Coronavirus worldwide
  • m
    mp
    Shipments are being sent to the U.S. It not only tests for Covid-19 but 20 other respiratory viruses. Returns results in about an hour. Good news.
  • K
    Ken
    Back to $38-$40 today. Way oversold yesterday
  • K
    K B B
    this should be 40s. Dow futures down 300. Two front runners with coronavirus diags,
    QGEN and CODX. QGEN is established company and more reliable.
  • T
    Thai
    Guys, no need to be panic. This is worth more than $40!
  • J
    John
    Great overview on sequencing versus mapping from here:
    https://www.reddit.com/r/BNGO/comments/l49l79/found_this_guy_on_twitter_he_explains_bngo_so/

    "
    First, the Saphyr mapper is not a sequencer, it is, as its name say, a mapper. The difference of a genome sequence and a genome map is that the map aids to decipher the sequence more accurately (for sequence I refer to billions of ATCGATCG…).

    A genome map is created before the sequencing begins and provides confidence in the sequence obtained. Therefore, the Saphyr mapper, does not compete or substitute any sequencing technology (either from $PACB, $ILMN, $TMO, etc.), but rather it is —COMPLEMENTARY— to it.

    For an analogy, think of an any given address. Imagine I live at 14th Main street, Springfield, Massachusetts, USA. And someone asks me where I live, and I simply answer “Springfield”. If the person is local of Massachusetts, will probably assume that I live in Springfield MA.

    However, if I’m asked in a state other than MA, and the person is from a state other than MA, will probably ask “which Springfield”, as there are many cities with this name in all USA; I would have to specify “Springfield, MA.”

    If you are familiar with the locality, you will probably assume its broader location. I use this analogy because almost every city in USA has a “Main” street; a lot of states have a “Springfield” city; but also, Main street in Springfield do exists in countries other than USA.

    Following this analogy, if we asked, “what is your address?” the most common different sequencing technologies will give, with great precision, the following answers: $ILMN — 14th Main. $TMO — 14th Main. $QGEN — 14th Main. $PACB — 14th Main, Springfield.

    None of the above will mention “MA, USA”. Is it possible to locate the accurate address with the first three? NO. Is it possible to locate it with PACB? NOT ENTIRELY.

    In the same analogy, if you asked the Saphyr mapper “what is your address?” the answer will be:

    $BNGO — Near Main, Springfield, MA, USA.

    Would you be able to know the precise address? NO. Therefore, there is no technology that could give a complete and accurate answer, yet.

    10) Then why is Bionano’s such a big deal? Because currently, the most common tools for mapping at hospitals and clinics around the world are FISH (fluorescent in situ hybridization), DNA microarrays (commonly known as CMA), chromosome banding (CB), and Karyotypes;

    11) these techniques have existed for at least 20 years and have been the state of the art, so far. What they all have in common is that they are laborious, time consuming and will answer the following to the question “what is your address?”:

    12)

    Karyotype — USA

    Microarays — Springfield

    FISH — MA

    Cromosome banding — Springfield or MA.

    Why is it that people compare Saphyr to PACB? As you can see, the state of the art for the highest precision was held by PACB, but still it won’t give a fully accurate address.

    13) So, if hospitals and clinics around the world needed to figure out what is wrong with your genes at a large scale with the most accurate map/sequence, the only option was PACB.

    14) The biggest disadvantage, however, is that, from all technologies mentioned, PACB is the most expensive and time consuming, and it needs a special expertise that is difficult to find in sequence analysis, hence not many clinics or hospitals even offer this service.

    15) Why is Bionano’s tech the such a big deal? Because it is only as expensive as any of the other mapping tools, it is high throughput, it covers the entire genome(s) at once, it is automated, and it is way more precise than FISH, CMA, CB, and Karyotypes ALL TOGETHER.

    16) Finally, the Saphyr mapper will inexorably find chromosomal re-arrengements missed by PACB—as we all have seen it in their webinars and scientific papers— because they resemble that Springfield was erroneously located in MA, USA—but is rather located in Chelmford, UK.

    17) Why is such a game changer then? Because, if combined, a Saphyr mapper and a sequencing technology (see above) will never miss a mutation or chromosome rearrangement — for large or small this is.

    18) My forecast for the upcoming years is that there will be a massive adoption of mapping tech at hospitals and clinics around the world in the next 5-10 years, which will substitute entirely FISH, CMA, CB, and Karyotypes.

    19) Maybe, if Bionano’s tech is the only one offering optical imaging, it will dominate the entire industry for years.

    As for $BNGO stock price, I have no idea; I am only a scientist that happens to trade.The stock market behaves in ways unpredictable to me.

    20) The only thing I'm certain is that Bionano’s tech is highly disruptive in its niche. And, if there is one thing I've learned from the Market, is that one thing is the company, another thing is its product/service, and a way different beast is its stock price.
  • S
    Sooveed
    So they are acquiring all of these shares at $50.73
  • r
    r
    Any chance a company comes back at 50?
  • H
    Hubert
    Bought at $54.12. Just watching this rocket ship.